李彤（教授）檢視原始碼討論檢視歷史
 |
李彤，女，北京大學基礎醫學院教授。
人物履歷
本科畢業於北京農業大學，碩士畢業於清華大學，博士畢業於瑞典Ume？大學。從進入大學起，從未離開過微生物學領域，從事過農業、環境、工業和醫學微生物學研究工作。是北京微生物學會第八、九和十屆理事，第二屆中國微生物學會臨床微生物學專業委員會流行病學組委員，中聯肝健康促進中心理事。擔任Journal of Medical Virology、Journal of Virological Methods、Antiviral Therapy、Antiviral Research、Journal of Viral Hepatitis、Infection Genetics and Evolution、Infection and Drug Resistance等國際學術期刊和多家中文學術期刊的同行評審專家。
研究方向
乙型肝炎病毒（HBV）感染，特別是慢性感染，可引起慢性乙型肝炎、肝硬化和肝癌等嚴重後果，是重大的公共衛生問題，2016年世界衛生組織提出了「2030年消除病毒性肝炎的威脅」的目標。目前HBV感染可預防、可診斷、可治療，但慢性感染難以徹底治癒。
HBV是易變異的病毒，我們以HBV變異及其生物學和臨床意義為研究方向，應用病毒學、分子生物學和免疫學等技術方法，結合臨床病例，開展基礎和臨床相結合的研究。從臨床標本分析入手，發現和鑑定有意義的病毒突變類型，並在體外研究突變株對病毒生物學特性、耐藥性、致病性、免疫逃逸等特性的影響和機制，已發表一系列相關研究論文，曾獲得秦皇島市科技進步一等獎、河北省科學技術進步獎三等獎、北京大學基礎醫學院SCI論文引用獎和優秀SCI論文獎等獎勵。
科研課題
本人曾承擔和參與多項國家級科研課題，目前在研課題為：
（1）國自然面上項目「揭示乙型肝炎表面抗原新突變對病毒複製的影響及突變株傳播的新途徑」的課題負責人；
（2）十三五傳染病重大專項課題「乙型肝炎臨床治癒及疾病進展相關的新生物標誌物及預測模型建立」任務負責人；
（3）十三五傳染病重大專項課題「艾滋病疫苗研究」任務負責人。
學術成果
論文
1. Hao R, Xiang K, Shi Y, Zhao D, Tian H, Xu B, Zhu Y, Dong H, Ding H, Zhuang H, Hu Jand Li T. Naturally occurring mutations within HBV surface promoter II sequences affect transcription activity, HBsAg and HBV DNA levels in HBeAg-positive chronic hepatitis B patients. Viruses. 2019, 11(1): 78. (co-corresponding author)
2. Xiang K, Xiao Y, Li Y, He L, Wang L, Zhuang H and Li T. The effect of the hepatitis B virus surface protein truncated sC69？mutation on viral infectivity and the host innate immune response. Front Microbiol. 2019, 10:1341. (co-corresponding author)
3. He L, Su M, Ou G, Wang L, Deng J, Zhuang H, Xiang K and Li T. The modulation of HBsAg level by sI126T is affected by additional amino acid substitutions in the S region of HBV. Infect Genet Evol. 2019, 75:104006. (co-corresponding author)
4. Xiang K, Zhao C, Wang S, Li Y, Su M, Wang Q, Xu X, Deng J, Zhuang H and Li T. Impacts of HBV rtH55R polymerase substitution on viral replication and rtM204I/V resistance to nucleoside/nucleotide antiviral drugs. Antivir Ther. 2018, 23(1): 33-42. (corresponding author)
5. Liu B, Yang J, Yan L, Zhuang H and Li T. Novel HBV recombinants between genotypes B and C in 3'-terminal reverse transcriptase (RT) sequences are associated with enhanced viral DNA load, higher RT point mutation rates and place of birth among Chinese patients. Infect Genet Evol. 2018, 57: 26-35. (co-corresponding author)
6. Li Y, He L, Li Y, Su M, Su J, Hou J, Deng J, Wang S, Wang Q, Xu X, Zhuang H and Li T. Characterization of serum HBV RNA in patients with untreated HBeAg-positive and -negative chronic hepatitis B infection. Hepatitis Monthly. 2018, 18(2):e62079. (co-corresponding author)
7. Su M, Liao L, Xing H, Wang S, Li Y, Lu W, He L, Deng J, Shao Y, Li T and Zhuang H. Characteristics of HBV infection in 705 HIV-infected patients under lamivudine-based antiretroviral treatment from three regions in China. Infect Drug Resist. 2018, 11: 1635-1644. (co-corresponding author)
8. Peng Y, Li Y, Hou J, Sun J, Su M, Li Y, Xiang K, Yan L, Zhuang H and Li T. The nucleotide changes within HBV core promoter/precore during the first 12 weeks of nucleos(t)ide treatment might be associated with a better virological response. Infect Genet Evol. 2017, 49: 116-121. (corresponding author)
9. Xiang KH, Michailidis E, Ding H, Peng YQ, Su MZ, Li Y, Liu XE, Dao Thi VL, Wu XF, Schneider WM, Rice CM, Zhuang H, Li T. Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA. J Hepatol. 2017. 66(2): p. 288-296. (co-corresponding author)
10. Xu X, Xiang K, Su M, Li Y, Ji W, Li Y, Zhuang H and Li T. HBV drug resistance substitutions existed before the clinical approval of nucleos(t)ide analogues: a bioinformatic analysis by GenBank data mining. Viruses. 2017, 9(1998): 199. (co-corresponding author)
11. Su M, Xiang K, Li Y, Li Y, Deng J, Xu X, Yan L, Zhuang H, Li T. Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2. Infect Genet Evol. 2016, 40:275-81. (co-corresponding author)
12. Peng Y, Liu B, Hou J, Sun J, Hao R, Xiang K, Yan L, Zhang J, Zhuang H, Li T. Naturally occurring deletions/insertions in HBV core promoter tend to decrease in hepatitis B e antigen-positive chronic hepatitis B patients during antiviral therapy. Antivir Ther. 2015, 20(6):623-32. (co-corresponding author)
13. Hao R, Xiang K, Peng Y, Hou J, Sun J, Li Y, Su M, Yan L, Zhuang H, Li T. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment. Infect Genet Evol. 2015, 33:261-8. (co-corresponding author)
14. Ding H, Liu B, Zhao C, Yang J, Yan C, Yan L, Zhuang H,Li T. Amino acid similarities and divergences in the small surface proteins of genotype C hepatitis B viruses between nucleos(t)ide analogue-naive and lamivudine-treated patients with chronic hepatitis B. Antiviral Res. 2014. 102: 29-34. (corresponding author)
15. Yan CH, Zhao CY, Ding H, Peng YQ, Jin PY, Yan L, Zhuang H, Li T. Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients. Antiviral Res. 2012, 96(2):108-14. (co-corresponding author)
16. Li XG, Liu BM, Xu J, Liu XE, Ding H, Li T. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. J Med Virol. 2012, 84(2):207-16. (co-corresponding author)
17. Yang JX, Liu BM, Li XG, Yan CH, Xu J, Sun XW, Wang YH, Jiao XJ, Yan L, Dong JP, Hou CS, Abuduheilili X, Li T, Zhuang H. Profile of antiviral resistance mutations within HBV reverse transcriptase in distinct evolutionary pathways refractory to nucleos(t)ide analogue treatment among Chinese patients with chronic HBV infection. Antiv Ther. 2010, 15(8): 1171-8. (co-corresponding author)
18. Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, Yang JX, Yan L, Gao ZY, Li WP, Sun XW, Wang YH, Jiao XJ, Hou CS, Zhuang H. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment na？ve Chinese patients. Antivir Res. 2010, 85(3):512-9. (co-corresponding author)
19. Du H, Li T, Zhang HY, He ZP, Dong QM, Duan XZ, Zhuang H. Correlation of hepatitis B virus (HBV) genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection. Liver Int. 2007, 27(2):240-6. (co-first author)[1]